<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35338174</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity.</ArticleTitle>
        <Pagination>
          <StartPage>5205</StartPage>
          <MedlinePgn>5205</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">5205</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-08937-z</ELocationID>
        <Abstract>
          <AbstractText>Representative models are needed to screen new therapies for patients with cancer. Cancer organoids are a leap forward as a culture model that faithfully represents the disease. Mouse-derived cancer organoids (MDCOs) are becoming increasingly popular, however there has yet to be a standardized method to assess therapeutic response and identify subpopulation heterogeneity. There are multiple factors unique to organoid culture that could affect how therapeutic response and MDCO heterogeneity are assessed. Here we describe an analysis of nearly 3500 individual MDCOs where individual organoid morphologic tracking was performed. Change in MDCO diameter was assessed in the presence of control media or targeted therapies. Individual organoid tracking was identified to be more sensitive to treatment response than well-level assessment. The impact of different generations of mice of the same genotype, different regions of the colon, and organoid specific characteristics including baseline size, passage number, plating density, and location within the matrix were examined. Only the starting size of the MDCO altered the subsequent growth. These results were corroborated using ~ 1700 patient-derived cancer organoids (PDCOs) isolated from 19 patients. Here we establish organoid culture parameters for individual organoid morphologic tracking to determine therapeutic response and growth/response heterogeneity for translational studies.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>DeStefanis</LastName>
            <ForeName>Rebecca A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Kratz</LastName>
            <ForeName>Jeremy D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin Carbone Cancer Center, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Olson</LastName>
            <ForeName>Autumn M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sunil</LastName>
            <ForeName>Aishwarya</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>DeZeeuw</LastName>
            <ForeName>Alyssa K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gillette</LastName>
            <ForeName>Amani A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sha</LastName>
            <ForeName>Gioia C</ForeName>
            <Initials>GC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Katherine A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pasch</LastName>
            <ForeName>Cheri A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin Carbone Cancer Center, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clipson</LastName>
            <ForeName>Linda</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skala</LastName>
            <ForeName>Melissa C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin Carbone Cancer Center, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Morgridge Institute for Research, Madison, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deming</LastName>
            <ForeName>Dustin A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 6507 WIMR2, Madison, WI, 53705, USA. ddeming@medicine.wisc.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Wisconsin Carbone Cancer Center, Madison, WI, USA. ddeming@medicine.wisc.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI, USA. ddeming@medicine.wisc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R37 CA226526</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 AG000213</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA185747</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA185747</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA226526</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA211082</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA009135</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA014520</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA205101</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 HL145792</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009940" MajorTopicYN="Y">Organoids</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Dr. Deming has participated in advisory boards and received research funding from Bayer, Takeda and Eli Lilly. The other authors declare no potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35338174</ArticleId>
        <ArticleId IdType="pmc">PMC8956720</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-08937-z</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-08937-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>American Cancer Society. Key statistics for colorectal cancer. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html. Accessed 19 August 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Fight Colorectal Cancer. https://fightcolorectalcancer.org/about-colorectal-cancer/general-information/facts-stats/. Accessed 19 August 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Benson AB, et al.  Colon cancer, Version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 2021;19:329–359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33724754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tveit KM, Pihl A. Do cell lines in vitro reflect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts. Br. J. Cancer. 1981;44:775–786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2010864</ArticleId>
            <ArticleId IdType="pubmed">7326190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esquenet M, Swinnen JV, Heyns W, Verhoeven G. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J. Steroid Biochem. Mol. Biol. 1997;62:391–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9449242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniel VC, et al.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–3373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2821899</ArticleId>
            <ArticleId IdType="pubmed">19351829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue X, Shah YM. In vitro organoid culture of primary mouse colon tumors. J. Vis. Exp. 2013;17:e50210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3684363</ArticleId>
            <ArticleId IdType="pubmed">23711911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Wetering M, et al.  Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6428276</ArticleId>
            <ArticleId IdType="pubmed">25957691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauli C, et al.  Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5413423</ArticleId>
            <ArticleId IdType="pubmed">28331002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasch CA, et al.  Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin. Cancer Res. 2019;25:5376–5387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726566</ArticleId>
            <ArticleId IdType="pubmed">31175091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachogiannis G, et al.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920–926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6112415</ArticleId>
            <ArticleId IdType="pubmed">29472484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashley N, Jones M, Ouaret D, Wilding J, Bodmer WF. Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalized therapeutic assays. J. Pathol. 2014;234:34–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24797403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dijkstra KK, et al.  Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174:1586–1598 e1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6558289</ArticleId>
            <ArticleId IdType="pubmed">30100188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesh K, et al.  A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 2019;25:1607–1614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7385919</ArticleId>
            <ArticleId IdType="pubmed">31591597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondo J, et al.  Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2011;108:6235–6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3076886</ArticleId>
            <ArticleId IdType="pubmed">21444794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schutte M, et al.  Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 2017;8:14262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5309787</ArticleId>
            <ArticleId IdType="pubmed">28186126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher D, et al.  Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet. 2019;15:e1008076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6457557</ArticleId>
            <ArticleId IdType="pubmed">30925167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson KA, et al.  Human colon organoids and other laboratory strategies to enhance patient treatment selection. Curr. Treat. Options Oncol. 2020;21:35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7924903</ArticleId>
            <ArticleId IdType="pubmed">32328818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharick JT, et al.  Cellular metabolic heterogeneity in vivo is recapitulated in tumor organoids. Neoplasia. 2019;21:615–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6514366</ArticleId>
            <ArticleId IdType="pubmed">31078067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weeber F, et al.  Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc. Natl. Acad. Sci. U.S.A. 2015;112:13308–13311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4629330</ArticleId>
            <ArticleId IdType="pubmed">26460009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnadottir SS, et al.  Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient-derived spheroid cultures. Mol. Oncol. 2018;12:132–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5748486</ArticleId>
            <ArticleId IdType="pubmed">29130628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dangles-Marie V, et al.  Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res. 2007;67:398–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17210723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullins CS, et al.  Integrated biobanking and tumor model establishment of human colorectal carcinoma provides excellent tools for preclinical research. Cancers (Basel) 2019;11:1520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6826890</ArticleId>
            <ArticleId IdType="pubmed">31601052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boehnke K, et al.  Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures. J. Biomol. Screen. 2016;21:931–941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5030729</ArticleId>
            <ArticleId IdType="pubmed">27233291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan N, et al.  A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2019;2:78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6389967</ArticleId>
            <ArticleId IdType="pubmed">30820473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boretto M, et al.  Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat. Cell Biol. 2019;21:1041–1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31371824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopper O, et al.  An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 2019;25:838–849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31011202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponz-Sarvise M, et al.  Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer. Clin. Cancer Res. 2019;25:6742–6755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6858952</ArticleId>
            <ArticleId IdType="pubmed">31492749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunil A, et al.  Abstract 1494: Etiologies of patient-derived colorectal cancer organoid growth heterogeneity across multiple patient samples and culture conditions. Cancer Res. 2020;80:1494–1494.</Citation>
        </Reference>
        <Reference>
          <Citation>Gil DA, Deming D, Skala MC. Patient-derived cancer organoid tracking with wide-field one-photon redox imaging to assess treatment response. J. Biomed. Opt. 2021;26:036005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7983069</ArticleId>
            <ArticleId IdType="pubmed">33754540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoetemelk M, Rausch M, Colin DJ, Dormond O, Nowak-Sliwinska P. Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma. Sci. Rep. 2019;9:7103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506470</ArticleId>
            <ArticleId IdType="pubmed">31068603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaushik G, et al.  Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Oncogene. 2021;40:848–862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7848971</ArticleId>
            <ArticleId IdType="pubmed">33288882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharick JT, et al.  Metabolic heterogeneity in patient tumor-derived organoids by primary site and drug treatment. Front. Oncol. 2020;10:553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7242740</ArticleId>
            <ArticleId IdType="pubmed">32500020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie BY, Wu AW. Organoid culture of isolated cells from patient-derived tissues with colorectal cancer. Chin. Med. J. (Engl.) 2016;129:2469–2475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072260</ArticleId>
            <ArticleId IdType="pubmed">27748340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boj SF, et al.  Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4334572</ArticleId>
            <ArticleId IdType="pubmed">25557080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin X, et al.  Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat. Methods. 2014;11:106–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3951815</ArticleId>
            <ArticleId IdType="pubmed">24292484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato T, et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011;141:1762–1772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21889923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao Y, et al.  Aging-like spontaneous epigenetic silencing facilitates Wnt activation, stemness, and Braf(V600E)-induced tumorigenesis. Cancer Cell. 2019;35:315–328 e316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6636642</ArticleId>
            <ArticleId IdType="pubmed">30753828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam MO, et al.  Effects of a small molecule R-spondin-1 substitute RS-246204 on a mouse intestinal organoid culture. Oncotarget. 2018;9:6356–6368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5814218</ArticleId>
            <ArticleId IdType="pubmed">29464078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fricke SL, et al.  MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol. Cancer Ther. 2019;18:346–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6363831</ArticleId>
            <ArticleId IdType="pubmed">30425131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glass GV, McGraw B, Smith ML.  Meta-analysis in Social Research. Sage; 1981. </Citation>
        </Reference>
        <Reference>
          <Citation>Foley TM, et al.  Dual PI3K/mTOR inhibition in colorectal cancers with APC and PIK3CA mutations. Mol. Cancer Res. 2017;15:317–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5550373</ArticleId>
            <ArticleId IdType="pubmed">28184015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sambuy Y, et al.  The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 2005;21:1–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15868485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang-Liu CM, Woloschak GE. Effect of passage number on cellular response to DNA-damaging agents: Cell survival and gene expression. Cancer Lett. 1997;113:77–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9065805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74:2377–2384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24717177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnes, L., Healy, J. &amp; Melville, J. UMAP: Uniform manifold approximation and projection for dimension reduction. arXiv:1802.03426v3 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 2020;15:3380–3409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32929210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broutier L, et al.  Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 2017;23:1424–1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5722201</ArticleId>
            <ArticleId IdType="pubmed">29131160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ooft SN, et al.  Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 2019;11:eaay2574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31597751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullenders J, et al.  Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proc. Natl. Acad. Sci. U.S.A. 2019;116:4567–4574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6410883</ArticleId>
            <ArticleId IdType="pubmed">30787188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duarte AA, et al.  BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nat. Methods. 2018;15:134–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29256493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohmussaar K, et al.  Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. Nat. Commun. 2020;11:2660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7253462</ArticleId>
            <ArticleId IdType="pubmed">32461556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hai J, et al.  Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy. Clin. Cancer Res. 2020;26:3431–3442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7334092</ArticleId>
            <ArticleId IdType="pubmed">32209571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kratz JD, et al.  Integrating subclonal response heterogeneity to define cancer organoid therapeutic sensitivity. bioRxiv. 2021 doi: 10.1101/2021.10.15.464556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.10.15.464556</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hung KE, et al.  Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. U.S.A. 2010;107:1565–1570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824379</ArticleId>
            <ArticleId IdType="pubmed">20080688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saam JR, Gordon JI. Inducible gene knockouts in the small intestinal and colonic epithelium. J. Biol. Chem. 1999;274:38071–38082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10608876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Killick, R. &amp; Eckley, I. A. Changepoint: An R package for changepoint analysis. https://www.jstatsoft.org/article/view/v058i03. J. Stat. Softw.58 (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Bowman, A. W., &amp; Assalini, A. R package 'sm': Nonparametric smoothing methods (version 2.2-5.4). http://www.stats.gla.ac.uk/~adrian/sm, http://azzalini.stat.unipd.it/Book_sm (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, 2021). https://www.R-project.org/</Citation>
        </Reference>
        <Reference>
          <Citation>Wickham H.  ggplot2: Elegant graphics for data analysis. Springer; 2016. </Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
